BIOMAT Database Logo BIOMAT Database Logo

Anti-HERV-K (HML-2) capsid antibody responses in HIV elite controllers. 2017

Miguel de Mulder, and Devi SenGupta, and Steven G Deeks, and Jeffrey N Martin, and Christopher D Pilcher, and Frederick M Hecht, and Jonah B Sacha, and Douglas F Nixon, and Henri-Alexandre Michaud
Department of Microbiology, Immunology, and Tropical Medicine, The George Washington University, Ross Hall 604, 2300 Eye St. NW, Washington, DC, 20037, USA. mdemulder@gwu.edu.

BACKGROUND Human endogenous retroviruses (HERVs) comprise approximately 8% of the human genome and while the majority are transcriptionally silent, the most recently integrated HERV, HERV-K (HML-2), remains active. During HIV infection, HERV-K (HML-2) specific mRNA transcripts and viral proteins can be detected. In this study, we aimed to understand the antibody response against HERV-K (HML-2) Gag in the context of HIV-1 infection. RESULTS We developed an ELISA assay using either recombinant protein or 164 redundant "15mer" HERV-K (HML-2) Gag peptides to test sera for antibody reactivity. We identified a total of eight potential HERV-K (HML-2) Gag immunogenic domains: two on the matrix (peptides 16 and 31), one on p15 (peptide 85), three on the capsid (peptides 81, 97 and 117), one on the nucleocapsid (peptide 137) and one on the QP1 protein (peptide 157). Four epitopes (peptides 16, 31, 85 and 137) were highly immunogenic. No significant differences in antibody responses were found between HIV infected participants (n = 40) and uninfected donors (n = 40) for 6 out of the 8 epitopes tested. The antibody response against nucleocapsid (peptide 137) was significantly lower (p < 0.001), and the response to QP1 (peptide 157) significantly higher (p < 0.05) in HIV-infected adults compared to uninfected individuals. Among those with HIV infection, the level of response against p15 protein (peptide 85) was significantly lower in untreated individuals controlling HIV ("elite" controllers) compared to untreated non-controllers (p < 0.05) and uninfected donors (p < 0.05). In contrast, the response against the capsid protein (epitopes 81 and 117) was significantly higher in controllers compared to uninfected donors (p < 0.001 and <0.05 respectively) and non-controllers (p < 0.01 and <0.05). Peripheral blood mononuclear cells (PBMCs) from study participants were tested for responses against HERV-K (HML-2) capsid recombinant peptide in gamma interferon (IFN-γ) enzyme immunospot (Elispot) assays. We found that the HERV-K (HML-2) Gag antibody and T cell response by Elispot were significantly correlated. CONCLUSIONS HIV elite controllers had a strong cellular and antibody response against HERV-K (HML-2) Gag directed mainly against the Capsid region. Collectively, these data suggest that anti-HERV-K (HML-2) antibodies targeting capsid could have an immunoprotective effect in HIV infection.

UI MeSH Term Description Entries
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D014764 Viral Proteins Proteins found in any species of virus. Gene Products, Viral,Viral Gene Products,Viral Gene Proteins,Viral Protein,Protein, Viral,Proteins, Viral
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015683 Gene Products, gag Proteins coded by the retroviral gag gene. The products are usually synthesized as protein precursors or POLYPROTEINS, which are then cleaved by viral proteases to yield the final products. Many of the final products are associated with the nucleoprotein core of the virion. gag is short for group-specific antigen. Viral gag Proteins,gag Antigen,gag Gene Product,gag Gene Products,gag Polyproteins,gag Protein,gag Viral Proteins,Gene Product, gag,Retroviral Antigen gag Protein,gag Antigens,gag Gene Related Protein,gag Polyprotein,Antigen, gag,Antigens, gag,Polyprotein, gag,Polyproteins, gag,Protein, gag,Proteins, Viral gag,Proteins, gag Viral,Viral Proteins, gag,gag Proteins, Viral

Related Publications

Miguel de Mulder, and Devi SenGupta, and Steven G Deeks, and Jeffrey N Martin, and Christopher D Pilcher, and Frederick M Hecht, and Jonah B Sacha, and Douglas F Nixon, and Henri-Alexandre Michaud
HERV-K HML-2 diversity among humans.
April 2016, Proceedings of the National Academy of Sciences of the United States of America,
Miguel de Mulder, and Devi SenGupta, and Steven G Deeks, and Jeffrey N Martin, and Christopher D Pilcher, and Frederick M Hecht, and Jonah B Sacha, and Douglas F Nixon, and Henri-Alexandre Michaud
Ancient Adversary - HERV-K (HML-2) in Cancer.
January 2021, Frontiers in oncology,
Miguel de Mulder, and Devi SenGupta, and Steven G Deeks, and Jeffrey N Martin, and Christopher D Pilcher, and Frederick M Hecht, and Jonah B Sacha, and Douglas F Nixon, and Henri-Alexandre Michaud
HERV-K(OLD): ancestor sequences of the human endogenous retrovirus family HERV-K(HML-2).
October 2001, Journal of virology,
Miguel de Mulder, and Devi SenGupta, and Steven G Deeks, and Jeffrey N Martin, and Christopher D Pilcher, and Frederick M Hecht, and Jonah B Sacha, and Douglas F Nixon, and Henri-Alexandre Michaud
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers.
May 2009, AIDS (London, England),
Miguel de Mulder, and Devi SenGupta, and Steven G Deeks, and Jeffrey N Martin, and Christopher D Pilcher, and Frederick M Hecht, and Jonah B Sacha, and Douglas F Nixon, and Henri-Alexandre Michaud
Detection of HERV-K(HML-2) viral RNA in plasma of HIV type 1-infected individuals.
October 2006, AIDS research and human retroviruses,
Miguel de Mulder, and Devi SenGupta, and Steven G Deeks, and Jeffrey N Martin, and Christopher D Pilcher, and Frederick M Hecht, and Jonah B Sacha, and Douglas F Nixon, and Henri-Alexandre Michaud
Identification of differentially expressed HERV-K(HML-2) loci in colorectal cancer.
January 2023, Frontiers in microbiology,
Miguel de Mulder, and Devi SenGupta, and Steven G Deeks, and Jeffrey N Martin, and Christopher D Pilcher, and Frederick M Hecht, and Jonah B Sacha, and Douglas F Nixon, and Henri-Alexandre Michaud
Not all viruses cause disease: HERV-K(HML-2) in healthy human tissues.
October 2022, PLoS biology,
Miguel de Mulder, and Devi SenGupta, and Steven G Deeks, and Jeffrey N Martin, and Christopher D Pilcher, and Frederick M Hecht, and Jonah B Sacha, and Douglas F Nixon, and Henri-Alexandre Michaud
Allelic variation of HERV-K(HML-2) endogenous retroviral elements in human populations.
November 2004, Journal of molecular evolution,
Miguel de Mulder, and Devi SenGupta, and Steven G Deeks, and Jeffrey N Martin, and Christopher D Pilcher, and Frederick M Hecht, and Jonah B Sacha, and Douglas F Nixon, and Henri-Alexandre Michaud
Exploring HERV-K (HML-2) Influence in Cancer and Prospects for Therapeutic Interventions.
September 2023, International journal of molecular sciences,
Miguel de Mulder, and Devi SenGupta, and Steven G Deeks, and Jeffrey N Martin, and Christopher D Pilcher, and Frederick M Hecht, and Jonah B Sacha, and Douglas F Nixon, and Henri-Alexandre Michaud
Transcriptional profiling of HERV-K(HML-2) in amyotrophic lateral sclerosis and potential implications for expression of HML-2 proteins.
August 2018, Molecular neurodegeneration,
Copied contents to your clipboard!